Atara Biotherapeutics Inc (ATRA) Given Consensus Rating of “Hold” by Analysts

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have been given a consensus recommendation of “Hold” by the six research firms that are presently covering the firm. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $24.00.

ATRA has been the subject of several recent analyst reports. Citigroup Inc set a $10.00 price target on Atara Biotherapeutics and gave the stock a “sell” rating in a research note on Thursday, March 16th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 4th. Canaccord Genuity set a $47.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 18th. Finally, Jefferies Group LLC set a $23.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, December 12th.

Atara Biotherapeutics (NASDAQ:ATRA) opened at 21.25 on Tuesday. The stock’s 50 day moving average is $16.27 and its 200-day moving average is $17.10. Atara Biotherapeutics has a 52-week low of $12.45 and a 52-week high of $25.73. The stock’s market capitalization is $618.14 million.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, March 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.35. Equities research analysts anticipate that Atara Biotherapeutics will post ($3.70) EPS for the current fiscal year.

Your IP Address:

In related news, CEO Isaac E. Ciechanover sold 30,800 shares of the firm’s stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $19.38, for a total transaction of $596,904.00. Following the completion of the transaction, the chief executive officer now owns 725,951 shares of the company’s stock, valued at $14,068,930.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $14.27, for a total value of $85,620.00. Following the transaction, the executive vice president now directly owns 364,105 shares of the company’s stock, valued at approximately $5,195,778.35. The disclosure for this sale can be found here. In the last three months, insiders sold 133,195 shares of company stock valued at $2,288,178. Company insiders own 16.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Elkfork Partners LLC purchased a new position in shares of Atara Biotherapeutics during the fourth quarter valued at $135,000. Creative Planning purchased a new position in shares of Atara Biotherapeutics during the third quarter valued at $213,000. Franklin Street Advisors Inc. NC purchased a new position in shares of Atara Biotherapeutics during the third quarter valued at $214,000. BlackRock Inc. boosted its position in shares of Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the company’s stock valued at $272,000 after buying an additional 6,597 shares in the last quarter. Finally, Capital Impact Advisors LLC purchased a new position in shares of Atara Biotherapeutics during the third quarter valued at $299,000. 77.48% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024521/atara-biotherapeutics-inc-atra-given-consensus-rating-of-hold-by-analysts.html

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.